BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 19738431)

  • 21. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
    Canella A; Welker AM; Yoo JY; Xu J; Abas FS; Kesanakurti D; Nagarajan P; Beattie CE; Sulman EP; Liu J; Gumin J; Lang FF; Gurcan MN; Kaur B; Sampath D; Puduvalli VK
    Clin Cancer Res; 2017 Oct; 23(20):6215-6226. PubMed ID: 28679777
    [No Abstract]   [Full Text] [Related]  

  • 22. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
    Wang N; Sun P; Lv M; Tong G; Jin X; Zhu X
    Biomater Sci; 2017 May; 5(5):1041-1050. PubMed ID: 28378865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
    Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
    Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
    D'Alessandro G; Grimaldi A; Chece G; Porzia A; Esposito V; Santoro A; Salvati M; Mainiero F; Ragozzino D; Di Angelantonio S; Wulff H; Catalano M; Limatola C
    Oncotarget; 2016 May; 7(21):30781-96. PubMed ID: 27096953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A combined preclinical therapy of cannabinoids and temozolomide against glioma.
    Torres S; Lorente M; Rodríguez-Fornés F; Hernández-Tiedra S; Salazar M; García-Taboada E; Barcia J; Guzmán M; Velasco G
    Mol Cancer Ther; 2011 Jan; 10(1):90-103. PubMed ID: 21220494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
    Minea RO; Duc TC; Swenson SD; Cho HY; Huang M; Hartman H; Hofman FM; Schönthal AH; Chen TC
    PLoS One; 2020; 15(9):e0238238. PubMed ID: 32881880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model.
    Park EJ; Zhang YZ; Vykhodtseva N; McDannold N
    J Control Release; 2012 Nov; 163(3):277-84. PubMed ID: 23000189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcium-activated potassium channels mediated blood-brain tumor barrier opening in a rat metastatic brain tumor model.
    Hu J; Yuan X; Ko MK; Yin D; Sacapano MR; Wang X; Konda BM; Espinoza A; Prosolovich K; Ong JM; Irvin D; Black KL
    Mol Cancer; 2007 Mar; 6():22. PubMed ID: 17359538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
    Zhou Q; Gallo JM
    Neuro Oncol; 2009 Jun; 11(3):301-10. PubMed ID: 18971416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
    Cho HY; Wang W; Jhaveri N; Torres S; Tseng J; Leong MN; Lee DJ; Goldkorn A; Xu T; Petasis NA; Louie SG; Schönthal AH; Hofman FM; Chen TC
    Mol Cancer Ther; 2012 Nov; 11(11):2462-72. PubMed ID: 22933703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.
    Natsume A; Wakabayashi T; Ishii D; Maruta H; Fujii M; Shimato S; Ito M; Yoshida J
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):653-9. PubMed ID: 17564708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
    Rocha CR; Kajitani GS; Quinet A; Fortunato RS; Menck CF
    Oncotarget; 2016 Jul; 7(30):48081-48092. PubMed ID: 27344172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different effects of KCa and KATP agonists on brain tumor permeability between syngeneic and allogeneic rat models.
    Black KL; Yin D; Konda BM; Wang X; Hu J; Ko MK; Bayan JA; Sacapano MR; Espinoza AJ; Ong JM; Irvin D; Shu Y
    Brain Res; 2008 Aug; 1227():198-206. PubMed ID: 18602898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide.
    Sharma AK; Gupta L; Sahu H; Qayum A; Singh SK; Nakhate KT; Ajazuddin ; Gupta U
    Pharm Res; 2018 Jan; 35(1):9. PubMed ID: 29294212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
    Zhang X; Yu J; Zhao C; Ren H; Yuan Z; Zhang B; Zhuang J; Wang J; Feng B
    Biomed Pharmacother; 2019 Jan; 109():2192-2202. PubMed ID: 30551476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.
    Wyatt EA; Davis ME
    Mol Pharm; 2020 Feb; 17(2):717-721. PubMed ID: 31916770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.